Core Viewpoint - The company announced the approval of multiple proposals, including the reappointment of the internal control auditing accounting firm during the third meeting of the 11th Board of Directors [2] Group 1 - The company held its third meeting of the 11th Board of Directors on August 19 [2] - The board approved the proposal regarding the reappointment of the internal control auditing accounting firm [2]

上海第一医药股份有限公司 关于百联集团财务有限责任公司的风险持续评估报告 根据《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》的要 求，结合百联集团财务有限责任公司（以下简称"财务公司"）提供的《金融许可证》 《营业执照》等有关证件资料，上海第一医药股份有限公司（以下简称"公司"）对 财务公司的经营资质、内控制度建设、业务和风险状况及经营情况进行了评估。现将 有关情况报告如下： 一、财务公司基本情况 （一）企业基本信息 百联集团财务有限责任公司系 2013 年 5 月经国家金融监督管理总局（原中国银行 保险监督管理委员会）批准，于 2013 年 6 月 26 日正式成立，由百联集团有限公司（以 下简称"百联集团"）和上海百联集团股份有限公司共同出资的国有控股企业集团财 务有限责任公司。法定代表人：杨阿国；注册地：上海市黄浦区中山南路 315 号 8 楼； 注册资本 100,000 万元，其中：百联集团出资人民币 7.5 亿元，占注册资本的 75%；百 联股份出资人民币 2.5 亿元，占注册资本的 25%；企业法人营业执照注册号： 310101000624106；社会统一信用代码证号为 913 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2025-039 上海第一医药股份有限公司 2025 年半年度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海第一医药股份有限公司（以下简称"公司"）根据《上海证券交易所上市公司 自律监管指引第 3 号——行业信息披露（第四号——零售）》的相关要求，现将公司 2025 年半年度主要经营数据披露如下： 一、报告期门店变动情况 截至2025年 6月30日，公司拥有门店 208家（含加盟店42家），总经营面积 21,601.9 平方米（不含加盟及非经营性建筑面积）。2025 年 1-6 月，公司净增门店 2 家，新增门 店 15 家（其中直营 6 家，加盟 9 家），闭店调整 13 家。截至期末，门店区域分布如下： 单位：家 | 区域（上海市） | 2024 | 年期末 | 2025 | 年半年度 | | --- | --- | --- | --- | --- | | | 直营 | 加盟 | 直营 | 加盟 | | 徐汇区 | 36 | 5 | 36 | 4 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2025-040 上海第一医药股份有限公司 关于聘任财务报告审计会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示： 公司拟聘任 2025 年度财务报告审计会计师事务所的名称：上会会计师事务所（特殊 普通合伙）。 原聘任的财务报告审计会计师事务所的名称：立信会计师事务所（特殊普通合伙） （以下简称"立信"） 拟变更会计师事务所的原因：立信连续多年为上海第一医药股份有限公司（以下简 称"公司"）提供审计服务，已达到《国有企业、上市公司选聘会计师事务所管理办法》 （以下简称"《管理办法》"）所规定的服务年限。为更好保证审计工作的独立性与客观 性，并综合考虑公司业务发展和整体审计服务的需要，公司按照有关规定，拟聘任上会 为公司 2025 年度财务报告审计服务机构。立信对本次变更事宜无异议。 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 上会会计师事务所（特殊普通合伙）（以下简称"上会"）成立于 2013 年，组织形 式为特殊普 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2025-041 上海第一医药股份有限公司 关于续聘内部控制审计会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示： 公司拟聘任 2025 年度内部控制审计会计师事务所的名称：德勤华永会计师事务所 （特殊普通合伙）。 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 德勤华永会计师事务所（特殊普通合伙）（以下简称"德勤"）的前身是 1993 年 2 月成立的沪江德勤会计师事务所有限公司，于 2002 年更名为德勤华永会计师事务所有 限公司，于 2012 年 9 月经财政部等部门批准转制成为特殊普通合伙企业。德勤注册地 址为上海市黄浦区延安东路 222 号 30 楼。 德勤具有财政部批准的会计师事务所执业证书，并经财政部、中国证监会批准，获 准从事 H 股企业审计业务。德勤已根据财政部和中国证监会《会计师事务所从事证券服 务业务备案管理办法》等相关文件的规定进行了从事证券服务业务备案。德勤过去二十 多年来一直从事证券期货相关服 ...

证券代码：600833 证券简称：第一医药 公告编号：2025-042 上海第一医药股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第二次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 4 日 14 点 00 分 召开地点：上海市徐汇区小木桥路 681 号 20 楼第三会议室 (五)网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年9月4日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 4 日 至2025 年 9 月 4 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9 ...

证券代码：600833 证券简称：第一医药 公告编号：临 2025-038 上海第一医药股份有限公司 第十一届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示：本次董事会不存在否决议案，没有董事投反对/弃权票。 上海第一医药股份有限公司（以下简称"公司"）第十一届董事会第三次会议于 2025 年 8 月 8 日以邮件方式通知，于 2025 年 8 月 18 日下午在上海市徐汇区小木桥路 681 号 上海外经大厦 20 楼第三会议室召开。本次会议由董事长张海波先生召集并主持。本次 会议应参加表决董事为 9 名，委托表决 0 名，实际参加表决董事 9 名。会议的召开符合 有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定，会议形成的决议 合法、有效。 根据会议议程，本次会议审议通过以下事项： 一、公司《2025 年半年度报告及摘要》 具体内容详见同日刊载于上海证券交易所网站 www.sse.com.cn《上海第一医药股份 有限公司 2025 年半年度报告》及《上海第一医药股份有限公 ...

Core Viewpoint - The company reported a mixed performance in the first half of 2025, with revenue growth but a significant decline in net profit due to previous year's compensation payments [1] Financial Performance - The company achieved operating revenue of 999.7 million yuan, a year-on-year increase of 11.58% [1] - Net profit attributable to shareholders was 14.02 million yuan, a year-on-year decrease of 89.19% [1] - The company's net profit excluding non-recurring items was 9.01 million yuan, a year-on-year increase of 24.58% [1] Business Development - The company expanded its retail network, increasing the number of retail stores to 208, with over 10 new pet specialty stores added [2] - The first pet-friendly pharmacy in Shanghai was recognized by the Shanghai Commercial Association [2] - The company added 14 new medical insurance stores, raising the proportion of direct medical insurance stores to 75.30%, an increase of 7.64 percentage points from the previous year [2] - Online business grew by 38.5%, with O2O business increasing by 46.1% [2] - Cross-border sales of health products through its subsidiary in Hong Kong saw a 12.4% increase [2] Supply Chain Optimization - The company optimized procurement costs and strengthened non-pharmaceutical supply chain construction, with self-owned brand sales increasing by 67.4% [3] - The company established a private equity investment fund focusing on functional food sectors [3] Industry Trends - The retail pharmacy industry is experiencing an accelerated closure trend, with 39,228 stores expected to close in 2024, a closure rate of approximately 5.76% [3] - The industry is shifting from expansion to enhancing profitability through refined operations [4]

Financial Performance - The company's operating revenue for the first half of 2025 was approximately ¥996.60 million, representing an increase of 11.58% compared to ¥893.17 million in the same period last year[21]. - The total profit for the first half of 2025 decreased to approximately ¥17.74 million, down 89.60% from ¥170.59 million in the previous year[21]. - The net profit attributable to shareholders for the first half of 2025 was approximately ¥14.02 million, a decline of 89.19% compared to ¥129.79 million in the same period last year[21]. - The basic earnings per share for the first half of 2025 was ¥0.0629, down 89.19% from ¥0.5818 in the previous year[20]. - The net cash flow from operating activities increased to approximately ¥55.54 million, compared to a negative cash flow of ¥14.58 million in the same period last year[21]. - The company reported a significant decrease in total profit and net profit primarily due to the absence of compensation received from property expropriation in the previous year[22]. - The company achieved a 24.58% increase in net profit attributable to shareholders after deducting non-recurring gains and losses, indicating successful business expansion and cost reduction efforts[22]. - The weighted average return on net assets decreased by 11.2 percentage points to 1.25% compared to the previous year[22]. Market Trends - The retail pharmacy market in China is projected to decline by 2.2% in 2024, with a total market size of approximately ¥2,152.17 billion, reflecting a 1.3% decrease in the first five months of 2025[28]. - The online pharmacy market is expected to reach ¥3,292 billion in 2024, with a year-on-year growth of 9.6%, and online sales accounting for 35% of the overall retail pharmacy market[29][32]. - The number of retail pharmacies is decreasing, with 39,228 closures in 2024, resulting in a closure rate of approximately 5.76%, up from 3.8% in 2023[34]. Company Strategy and Development - The company ranked 45th in the 2024-2025 China Pharmacy Value Top 100 list, improving by 7 positions from the previous year[41]. - The company is focusing on enhancing core competitiveness and high-quality development in 2025, which is a key year for completing the "14th Five-Year Plan"[41]. - The retail pharmacy O2O market is projected to grow to ¥487 billion in 2024, with a year-on-year increase of 31.3%, significantly outpacing the industry average[32]. - The company is adapting to regulatory changes, including the introduction of electronic prescriptions and price governance measures, which are expected to impact operational strategies[35][38]. - The company is positioned to leverage the growing health consciousness among consumers, driven by an aging population and increasing healthcare spending[27]. - The company is enhancing its service offerings, including chronic disease management and health consultations, to align with new health consumption policies[39]. - The company is expected to face challenges from increased competition and regulatory scrutiny in the retail pharmacy sector, necessitating a shift towards refined operational strategies[39]. - The company expanded its retail store count to 208, adding over 10 pet specialty stores, and achieved a 75.30% share of direct medical insurance stores, up 7.64 percentage points year-over-year[42]. - Online business grew by 38.5% year-over-year, with O2O business increasing by 46.1%, driven by enhanced platform collaboration and promotional activities[46]. - The company established a private equity investment fund focusing on functional food sectors, aligning with Shanghai's strategic development plans for the health industry[47]. - The self-owned brand sales increased by 67.4% year-over-year, supported by the introduction of integrated supply chain products and strategic partnerships with suppliers[49]. - The company conducted over 900 community health service activities, enhancing brand reputation and community engagement[52]. - The company launched a chronic disease management service system, with over 60,000 members registered in the first half of 2025[50]. - The company introduced innovative store formats targeting specific consumer groups, such as health stations for young mothers, to diversify product offerings[43]. - The company accelerated the development of a modern intelligent logistics center, expected to significantly reduce logistics costs and improve delivery efficiency by 2025[50]. - The company added 14 new medical insurance stores during the reporting period, enhancing its service network[42]. - The company implemented a comprehensive training program for over 100 employees in various health-related qualifications, strengthening its talent pool[51]. Financial Management - The operating cost for the reporting period was approximately CNY 831.77 million, reflecting an increase of 11.90% from CNY 743.35 million year-on-year[58]. - The company reported a credit impairment reversal of CNY 1.40 million during the reporting period, compared to a loss of CNY 270,036 in the previous year[57]. - The company’s financial expenses decreased to CNY -4.58 million from CNY -7.21 million, indicating improved financial management[58]. - The company’s short-term borrowings decreased by 48% to CNY 49.70 million from CNY 95.58 million in the previous year[65]. - The total fair value of other equity investments increased by 6,852,870.07 RMB, reaching 259,338,029.44 RMB by the end of the period[71]. - The total fair value of trading financial assets increased significantly by 159,700,000.00 RMB, resulting in a total of 289,426,029.44 RMB[71]. Subsidiary Performance - The subsidiary, HSBC Pharmaceutical, reported a net profit of 2,243.70 million RMB, an increase of 86.30% compared to the previous period due to sales growth[76]. - The First Pharmaceutical Chain subsidiary recorded a net loss of 654.02 million RMB, showing improvement from a loss of 969.23 million RMB in the previous period[76]. - The total assets of HSBC Pharmaceutical reached 108,712.20 million RMB, with a net asset value of 10,999.50 million RMB[75]. - The subsidiary Deep Sea Pharmaceutical reported a net profit of 60.75 million RMB, a recovery from a loss of 15.73 million RMB in the previous period[76]. - The subsidiary HSBC Drugstore reported a net loss of 928.12 million RMB, attributed to increased costs from new store openings[76]. Regulatory and Compliance - The company faces risks from industry policy changes, including price control pressures and increased competition from online and offline channels[79]. - The company plans to enhance its management capabilities and innovate its business model in response to regulatory changes in the pharmaceutical industry[79]. - The company has committed to ensuring business independence for its subsidiary, with a focus on maintaining separate operations in procurement, production, and sales[88]. - The company guarantees that its subsidiary will have complete asset independence, ensuring that all operational licenses and related assets are fully owned or used by the subsidiary[89]. - The company will maintain financial independence for its subsidiary, including establishing an independent accounting department and financial management system[89]. - The company has committed to ensuring personnel independence for its subsidiary, with key management not receiving compensation from the parent company[89]. - There are no significant lawsuits or arbitration matters affecting the company during the reporting period[91]. - The company and its major stakeholders have maintained a good integrity status, with no major breaches of trust reported[91]. - The company has not engaged in any non-operational fund occupation by major shareholders or related parties during the reporting period[90]. - There are no violations or guarantees reported during the reporting period[90]. - The company has not received any non-standard audit opinions in the previous annual report[91]. - The company has committed to avoiding any competitive business activities with its parent company during the reporting period[88]. - The company plans to engage in daily operational related party transactions with its controlling shareholder, Bailian Group Co., Ltd., and its subsidiaries for the year 2025[92]. Shareholder Information - The total number of ordinary shareholders as of the reporting period end is 24,694[111]. - The largest shareholder, Bailian Group Co., Ltd., holds 44.95% of the shares, totaling 100,274,734 shares[113]. - Jilin Aodong Pharmaceutical Group Co., Ltd. holds 4.93% of the shares, totaling 10,988,525 shares[113]. - The company has not reported any changes in its share capital structure during the reporting period[110]. - The company has not entered into any other significant contracts during the reporting period[107]. - There are no overdue guarantees or contingent liabilities related to guarantees[106]. Cash Flow and Assets - The total current assets as of June 30, 2025, amounted to CNY 1,155,783,284.13, an increase from CNY 1,127,001,836.27 as of December 31, 2024, reflecting a growth of approximately 2.3%[120]. - Cash and cash equivalents decreased to CNY 370,767,879.28 from CNY 436,420,035.77, representing a decline of about 15.0%[120]. - Accounts receivable decreased to CNY 157,935,555.44 from CNY 189,373,266.78, indicating a reduction of approximately 16.6%[120]. - Inventory increased significantly to CNY 424,789,975.34 from CNY 336,323,956.50, marking an increase of around 26.3%[120]. - Non-current assets totaled CNY 1,006,778.53 for long-term equity investments, remaining unchanged from the previous period[120]. - The company's total liabilities and equity structure was not detailed in the provided content, indicating a focus on asset management rather than liabilities[120]. - The company reported a notable increase in other equity instrument investments to CNY 269,726,029.44 from CNY 252,873,159.37, reflecting a growth of approximately 6.7%[120]. - The fixed assets slightly decreased to CNY 83,867,352.97 from CNY 85,146,139.48, a decline of about 1.5%[120]. Accounting Policies - The financial statements are prepared based on the "Enterprise Accounting Standards" and relevant regulations, ensuring a true and complete reflection of the company's financial status and operating results[152]. - The accounting period for the company runs from January 1 to December 31 each year[153]. - The company's accounting currency is Renminbi, while its subsidiary in Hong Kong uses US dollars[155]. - The company has established materiality thresholds for various accounting estimates, such as a single bad debt provision exceeding 10% of total receivables being considered significant[156]. - The company follows specific accounting treatments for mergers, including measuring assets and liabilities based on their book value at the merger date for same-control mergers[157]. - Directly related expenses incurred during mergers are recognized in the current period's profit and loss[158]. - The company consolidates financial statements based on control, including all subsidiaries, and offsets internal transactions[159]. - The company recognizes the operating results and cash flows of newly acquired subsidiaries from the beginning of the reporting period[160]. - Upon losing control of a subsidiary, the remaining equity investment is remeasured at fair value on the date control is lost[161]. - The company adjusts capital reserves for differences arising from the purchase of minority stakes in subsidiaries[163]. - The company confirms its share of assets and liabilities related to joint operations, recognizing both individually held assets and those shared according to its ownership percentage[164]. Inventory Management - Inventory is classified into categories such as finished goods and raw materials, and is measured at cost, including procurement and processing costs[182]. - The company uses a perpetual inventory system and applies the weighted average method for inventory valuation upon issuance[184]. - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs recognized when costs exceed net realizable values[183]. - The company assesses the net realizable value of inventory based on estimated selling prices minus estimated costs to complete and sell the inventory[183]. - Provisions for inventory write-downs can be reversed if the factors leading to the write-down no longer exist, with the reversal amount recognized in current profit or loss[185]. - Low-value consumables and packaging materials are expensed using a one-time write-off method[186]. Financial Instruments - Financial assets are classified at initial recognition as either measured at amortized cost, fair value through other comprehensive income, or fair value through profit or loss[167]. - Financial liabilities are classified at initial recognition as either fair value through profit or loss or measured at amortized cost[169]. - The company recognizes financial assets when it becomes a party to the financial instrument contract, including financial assets, financial liabilities, or equity instruments[171]. - Financial assets are derecognized when the contractual rights to cash flows expire or when the asset is transferred and the risks and rewards of ownership are substantially transferred[173]. - The company uses the effective interest method to calculate interest on financial assets measured at amortized cost, with gains or losses recognized upon derecognition[172]. - The company can irrevocably designate non-trading equity investments as fair value through other comprehensive income at initial recognition[168]. - The company recognizes foreign currency transactions at the spot exchange rate on the transaction date, with any exchange differences recognized in profit or loss[165]. - The company will transfer cumulative gains or losses from other comprehensive income to profit or loss upon derecognition of financial assets[171]. - The company terminates the recognition of financial liabilities when the current obligations are fully or partially discharged, and any difference between the carrying amount and the consideration paid is recognized in the current profit or loss[175]. - Fair value of financial assets and liabilities is determined using observable inputs from active markets, or valuation techniques when active markets do not exist, prioritizing relevant observable inputs[176]. - The company assesses expected credit losses based on past events, current conditions, and forecasts of future economic conditions, with significant increases in credit risk leading to loss provisions based on the entire expected life of the financial instrument[179]. - For financial instruments with significant increases in credit risk, loss provisions are measured based on expected credit losses over the entire life, while those without significant increases are measured over the next 12 months[179].

Core Viewpoint - First Pharmaceutical (600833) reported a significant increase in revenue but a drastic decline in net profit for the first half of 2025, indicating potential challenges in profitability despite revenue growth [1] Financial Performance - The company achieved a revenue of 999.7 million yuan, representing a year-on-year growth of 11.58% [1] - The net profit attributable to shareholders was 14.02 million yuan, showing a year-on-year decrease of 89.19% [1] - Key financial metrics such as total profit, net profit attributable to shareholders, basic earnings per share, diluted earnings per share, and weighted average return on net assets all experienced a decline compared to the previous year [1] Explanation for Performance - The decline in profitability is primarily attributed to the previous year's compensation received from property expropriation, which significantly impacted the comparative financial results [1]